9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | -$3M | 21.1% | -154.0% | — | $2M | $18M |
| 2024 | $2M | -$3M | 28.7% | -130.4% | — | $1M | $12M |
| 2023 | $2M | -$6M | 21.6% | -284.4% | — | $293178 | $17M |
| 2022 | — | -$6M | — | — | — | — | $16M |
| 2021 | — | -$3M | — | — | — | $43414 | $13M |
| 2020 | — | -$10M | — | — | $803408 | $80413 | $7M |
| 2019 | — | $2M | — | — | -$296633 | $69523 | $9M |
| 2018 | — | $1M | — | — | $1M | — | $657767 |
| 2017 | — | $1M | — | — | $113866 | — | $65570 |
How the market has priced SXTC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, China SXT Pharmaceuticals, Inc.'s revenue has declined 6.0% per year. These are computed facts, not advice.
As of FY2025, China SXT Pharmaceuticals, Inc. reported $2M of total debt against $18M of cash; operating income covered interest expense -4.1×.
In FY2025, gross margin was 21.1%, operating margin -154.0%, and net margin -189.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.